Amira Pharmaceuticals Inc.
Division of Bristol-Myers Squibb Co.
www.amirapharm.com
Latest From Amira Pharmaceuticals Inc.
From Inception, Tempest Plans To Kick Up IO Storm
Emerging Company Profile: Spinning out of Versant Ventures’ Inception Sciences, San-Francisco-based development-stage biotech Tempest Therapeutics Inc. completes $70m Series B round to advance small molecules that modulate anti-tumor immunity pathways.
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
Versant Launches Inception IBD, A New Company With Old Roots
Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
-
Robert F Baltera, Jr., CEO
Michael V Swanson, CFO
Peppi Prasit, PhD, CSO - Contact Info
-
Amira Pharmaceuticals Inc.
Phone: (858) 228-4650
9535 Waples St.
Ste. 100
San Diego, CA 92121
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice